12/4
06:55 am
halo
Halozyme downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Halozyme downgraded to Sell from Neutral at Goldman Sachs
12/4
06:55 am
halo
Halozyme downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Halozyme downgraded to Sell from Neutral at Goldman Sachs
12/4
06:55 am
halo
Halozyme downgraded to Sell from Neutral at Goldman Sachs
Low
Report
Halozyme downgraded to Sell from Neutral at Goldman Sachs
11/28
07:02 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/18
12:54 pm
halo
Rating for HALO
Low
Report
Rating for HALO
11/18
12:54 pm
halo
Rating for HALO
Low
Report
Rating for HALO
11/18
12:54 pm
halo
Rating for HALO
Low
Report
Rating for HALO
11/4
07:21 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
10/27
10:18 am
halo
Rating for HALO
Low
Report
Rating for HALO
10/21
08:45 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright.
10/20
11:34 am
halo
Rating for HALO
Low
Report
Rating for HALO
10/20
11:34 am
halo
Rating for HALO
Low
Report
Rating for HALO
10/15
08:12 am
halo
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $90.00 price target on the stock.
10/14
02:21 pm
halo
Rating for HALO
Low
Report
Rating for HALO
10/14
02:00 pm
halo
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Leerink Partners from an "underperform" rating to a "market perform" rating. They now have a $70.00 price target on the stock.
Low
Report
Halozyme Therapeutics (NASDAQ:HALO) was upgraded by analysts at Leerink Partners from an "underperform" rating to a "market perform" rating. They now have a $70.00 price target on the stock.
10/14
01:02 pm
halo
Halozyme upgraded to Market Perform from Underperform at Leerink
Low
Report
Halozyme upgraded to Market Perform from Underperform at Leerink
9/24
08:23 am
halo
Rating for HALO
Medium
Report
Rating for HALO
9/24
08:23 am
halo
Rating for HALO
Medium
Report
Rating for HALO